Live Research Database
Eczema
Hub: Dallas, TX
Connecting patients in Dallas with breakthrough clinical trials, specialized care, and study-related compensation.
+4k
Join 4,200+ participants tracking trials in Texas
Available Eczema Opportunities
12 RecruitingNCT06988605(Verify)
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
RECRUITING
Eczema
NCT07003425(Verify)
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING
Eczema
NCT07277660(Verify)
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
RECRUITING
Eczema
NCT05995964(Verify)
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
RECRUITING
Eczema
NCT06947993(Verify)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT07265479(Verify)
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING
Eczema
NCT06982352(Verify)
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING
Eczema
NCT06863961(Verify)
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
NCT07290803(Verify)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
RECRUITING
Eczema
NCT06241118(Verify)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING
Eczema
NCT06389136(Verify)
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING
Eczema
NCT07105488(Verify)
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
RECRUITING
Eczema
Patient Safeguards
IRB Oversight
Ethics Committee Approved
HIPAA Compliant
Full Data Privacy
NIH Standards
Global Quality Benchmarks
"Advancing Eczema research in Dallas through safe, transparent, and patient-first clinical trials."
Research Hubs in Dallas
Explore other local breakthroughs
Eczema Hubs in TX
Regional Network of Excellence
ClinicalTrials.govFDA REGISTEREDIRB OVERSIGHTHIPAA COMPLIANT